Next 10 |
2024-06-13 07:22:19 ET More on Voyager Therapeutics Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis Voyager Therapeutics up 8% following quarterly beats Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats...
2024-05-10 07:20:02 ET More on Vor Biopharma Seeking Alpha’s Quant Rating on Vor Biopharma Historical earnings data for Vor Biopharma Financial information for Vor Biopharma Read the full article on Seeking Alpha For further details see: Vo...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
2024-03-28 16:52:13 ET Gainers: Semtech Corporation ( SMTC ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Sagimet Biosciences ( SGMT ) +5% . Photronics ( PLAB ) +5% . James River Group Holdings ( JRVR ) +4% . Losers...
2024-03-22 16:59:35 ET Gainers: Masimo ( MASI ) +12% . Pliant Therapeutics ( PLRX ) +5% . Vor Biopharma ( VOR ) +5% . Vor Biopharma ( CNDT ) +4% . Xometry ( XMTR ) +4% . Losers: Airship AI Holdings ( AISP ) -7% . ...
2024-03-20 17:02:08 ET More on Vor Biopharma Seeking Alpha’s Quant Rating on Vor Biopharma Historical earnings data for Vor Biopharma Financial information for Vor Biopharma Read the full article on Seeking Alpha For further details see: Vo...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34 th Annual Healthcare Life Sciences Conferen...
First patient dosed in company’s second clinical program with initial data expected in second half of 2024 Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-sta...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...